United States Drug Patent 5,180,715: Scope, Claims, Expiration, and Pentosan Polysulfate Patent Landscape

US Patent 5,180,715 protected methods for treating bladder infections and interstitial cystitis with sodium pentosan polysulfate, including intravesical irrigation and oral administration. The patent issued on January 19, 1993, and its relevant US patent term expired in 2010. It no longer presents an enforceable US patent barrier to generic pentosan polysulfate products. Its historical importance is that it covered the therapeutic use underlying Elmiron, the FDA-approved oral sodium pentosan polysulfate product for interstitial cystitis.[1-3]

The patent is a use patent, not a composition-of-matter patent. It does not claim sodium pentosan polysulfate itself, a particular capsule, a manufacturing process, or a drug delivery device.

What does US Patent 5,180,715 protect?

US 5,180,715 protects administering sodium pentosan polysulfate to mammals for bladder-related conditions. Its claims divide into two treatment routes:

Claim group	Condition	Route	Key limitation
Claims 1-4	Bladder infections	Intravesical irrigation	Irrigating the internal bladder and associated surfaces
Claims 5-8	Interstitial cystitis	Intravesical irrigation	Sodium pentosan polysulfate in an irrigating solution
Claims 9-11	Interstitial cystitis	Oral administration	At least about 100 mg/day, or about 150-300 mg/day

The patent has 11 claims. Claims 1, 5, and 9 are independent. Claims 2-4, 6-8, and 10-11 narrow those independent claims by specifying saline or dosage concentration.

The claims do not require a specific commercial product, brand, capsule, excipient, treatment duration, dosing frequency, patient age, disease severity, or diagnostic test. The central limitations are the active ingredient, the disease or condition, and the route of administration.

How should the independent claims be interpreted?

Claim 1: bladder infection treatment by irrigation

Claim 1 covers:

A method;
Treating bladder infections;
In a mammal;
By irrigating the internal bladder and associated surfaces;
With an irrigating solution containing an effective amount of sodium pentosan polysulfate.

The claim is broad as to the irrigating solution. It does not require saline, and it does not specify a concentration. A solution containing an effective amount of sodium pentosan polysulfate can therefore fall within the literal language if the treatment is performed by bladder irrigation.

The phrase “associated surfaces” extends beyond the bladder lumen and may include surfaces reached during intravesical administration. The claim does not expressly require that the solution remain in the bladder for a specified period.

Claim 5: interstitial cystitis treatment by irrigation

Claim 5 has substantially the same structure as claim 1 but changes the indication from bladder infections to interstitial cystitis.

The claim covers intravesical treatment of interstitial cystitis using sodium pentosan polysulfate. It does not require a particular concentration, saline vehicle, instillation volume, or treatment schedule.

This distinction matters because a product or procedure can fall outside claim 1 by not treating a bladder infection while still implicating claim 5 if it is used to treat interstitial cystitis.

Claim 9: oral treatment of interstitial cystitis

Claim 9 covers:

A method;
Treating interstitial cystitis in a mammal;
By orally administering;
An effective amount of sodium pentosan polysulfate.

The claim does not specify a minimum dose. Claims 10 and 11 add daily-dose limitations:

Claim 10: at least about 100 mg per day.
Claim 11: about 150-300 mg per day.

The oral claim is the commercially significant portion of the patent because Elmiron is an oral capsule product indicated for relief of bladder pain or discomfort associated with interstitial cystitis.[2]

What formulations are protected by US 5,180,715?

US 5,180,715 does not claim a proprietary formulation in the conventional product-patent sense. It claims use of sodium pentosan polysulfate in an irrigating solution or through oral administration.

Intravesical formulations

Claims 1 and 5 cover an irrigating solution containing sodium pentosan polysulfate. Claims 2 and 6 narrow the vehicle to saline. Claims 3, 4, 7, and 8 specify concentration ranges:

Claims	Concentration
3 and 7	About 1-20 mg/mL
4 and 8	About 5-20 mg/mL

The 5-20 mg/mL range is a narrower subset of the 1-20 mg/mL range. A solution at 10 mg/mL would fall within both ranges, assuming the other claim elements are satisfied.

The patent does not require saline unless the asserted claim is 2 or 6. A non-saline vehicle may remain within claims 1 or 5, subject to the effective-amount and irrigation limitations.

Oral formulations

Claims 9-11 do not require a capsule, tablet, liquid, specific excipient, delayed-release coating, or particle size. An oral product could potentially satisfy the route and dosage elements regardless of dosage form, provided it administers sodium pentosan polysulfate for interstitial cystitis.

The claims therefore provide method coverage rather than direct coverage of every oral product containing the active ingredient.

How many patents cover sodium pentosan polysulfate and Elmiron?

The answer depends on whether the analysis is limited to US 5,180,715 or includes the broader Elmiron Orange Book and patent family landscape.

Patent category	US 5,180,715 status
Active ingredient composition	Not claimed
Intravesical use	Claimed
Oral interstitial cystitis use	Claimed
Saline irrigation	Narrowly claimed
Intravesical concentration	Narrowly claimed
Oral dose of at least 100 mg/day	Narrowly claimed
Oral dose of 150-300 mg/day	Narrowly claimed
Capsule formulation	Not expressly claimed
Manufacturing process	Not claimed
Device or delivery system	Not claimed

Historical FDA Orange Book listings for Elmiron included US 5,180,715 and other patents associated with the product. A separate patent, US 5,362,718, was also part of the historical Elmiron patent landscape and had a later expiration date than US 5,180,715.[3-5]

The existence of another listed patent does not expand the claims of US 5,180,715. Each patent must be analyzed independently by claim language, expiration date, and any applicable regulatory extension.

When did US Patent 5,180,715 expire?

US 5,180,715 expired in 2010 based on the applicable US patent-term calculation. The patent issued in 1993, but the governing term for this patent was tied to the statutory transition rules applicable to applications filed before June 8, 1995.[1,4]

Event	Date
Patent issued	January 19, 1993
Statutory term endpoint	2010
Enforceable patent status today	Expired

The expiration of the patent eliminates ordinary infringement liability for conduct occurring after expiration. A patent owner cannot use an expired patent to block a later generic launch or obtain ordinary post-expiration damages.

The patent’s expiration does not erase its historical relevance. It can remain relevant to prior-period litigation, validity analysis, prosecution-history review, and the timing of generic entry.

What was the FDA regulatory status of the covered drug?

FDA approved Elmiron under NDA 020193 for the relief of bladder pain or discomfort associated with interstitial cystitis. The approved product is sodium pentosan polysulfate sodium for oral use.[2]

The FDA-approved indication does not exactly replicate every phrase in claim 9. Claim 9 refers to treating interstitial cystitis, while the approved labeling describes relief of bladder pain or discomfort associated with the condition. The approved product and the patent nevertheless overlap commercially because both concern oral sodium pentosan polysulfate treatment for interstitial cystitis.

The product is not a biologic. Biosimilar provisions do not apply. Any follow-on product would proceed through the generic-drug framework, normally under an abbreviated new drug application rather than a biosimilar application.

What was the Orange Book status of US 5,180,715?

US 5,180,715 was historically associated with Elmiron’s FDA-listed patent protections. The Orange Book records patents submitted by NDA sponsors and identifies their expiration information for generic-drug regulatory review.[3]

Because the patent expired in 2010, it cannot now support a live Paragraph IV barrier. A Paragraph IV certification is relevant when an ANDA applicant challenges a listed patent that remains unexpired or otherwise affects approval timing. An expired patent does not provide a current 30-month stay mechanism.

The regulatory consequences are:

No current market exclusivity from US 5,180,715.
No current patent-based delay for an ANDA relying on the expired patent.
No current need for a generic applicant to design around the expired claims for US launch purposes.
Continued relevance only to historical ANDA certifications, litigation, or pre-expiration conduct.

FDA Orange Book patent listings and patent enforceability are related but separate issues. Listing does not extend the patent term.

Were there Paragraph IV challenges to the patent?

A Paragraph IV challenge could have been filed against US 5,180,715 while the patent was listed and unexpired. The available public record must be reviewed on a product-specific basis to identify the ANDA applicant, notice date, asserted claims, district-court venue, and settlement terms.

The practical conclusion is clear: any Paragraph IV dispute concerning this patent no longer creates a current US launch restriction because the patent expired in 2010.

A generic applicant would have had several possible positions:

The patent was expired or would expire before approval.
The patent was not infringed because the proposed product labeling did not induce the claimed method.
The claims were invalid for lack of patentable subject matter, anticipation, obviousness, written description, enablement, or indefiniteness.
The proposed product or use did not meet the route, indication, dosage, or irrigation limitations.

For the oral claims, induced-infringement analysis would have focused heavily on the product label. A generic label directed to interstitial cystitis treatment at the claimed dosage could have created greater risk than a label omitting or materially narrowing the patented indication, subject to FDA labeling requirements and the applicable skinny-label rules.

What litigation and settlement issues affect the patent?

US 5,180,715 could have supported litigation over four principal issues:

Claim construction

Courts would need to interpret:

“Bladder infections”
“Interstitial cystitis”
“Irrigating the internal bladder and associated surfaces”
“Effective amount”
“About 1 to 20 mg/ml”
“At least about 100 mg”
“About 150 to 300 mg”

The “about” language introduces numerical flexibility but does not eliminate the need to establish that a dose falls within the claimed range.

Induced infringement

The oral claims are method claims. A generic manufacturer would not directly administer the drug to patients. The principal theory would therefore involve induced infringement based on labeling, promotional materials, or other conduct encouraging oral use for interstitial cystitis.

Validity

The patent’s strength would have depended on prior art concerning pentosan polysulfate, bladder disease, glycosaminoglycan-layer repair, oral dosing, and intravesical therapy. The presence of broad therapeutic-use claims would have made prosecution history and priority support important, particularly for the “effective amount” language.

Settlement agreements

A pre-expiration settlement could have included a licensed entry date, restrictions on labeling, a covenant not to sue, or other commercial terms. After expiration, such a settlement would have no ability to delay entry based on US 5,180,715 alone.

No current settlement can preserve exclusivity after statutory patent expiration.

How strong was the patent estate for Elmiron?

The historical estate was moderate for the approved oral indication but limited in technical breadth.

Strengths

It covered oral treatment of interstitial cystitis.
It included dose-specific dependent claims.
It also covered intravesical use.
It aligned with the product’s approved therapeutic area.
Method claims could create label-based generic-entry risk before expiration.

Limitations

It did not claim sodium pentosan polysulfate as a compound.
It did not claim all formulations containing the active ingredient.
It did not claim a manufacturing process.
It did not create biosimilar-style exclusivity.
It depended on proof of the claimed therapeutic use and route.
It expired in 2010.

The patent was more valuable as a historical use barrier than as a long-term technology platform. Its commercial protection was vulnerable to expiration because the active ingredient itself was not protected by this patent.

What generic entry risks existed for Elmiron?

Before expiration, generic applicants faced risk from the oral method claims if their labeling encouraged treatment of interstitial cystitis with sodium pentosan polysulfate. The risk was highest for products labeled with:

The interstitial cystitis indication;
Oral administration;
Daily dosing of at least 100 mg;
A 150-300 mg daily dosage range.

A generic product with a label omitting the patented indication might have reduced induced-infringement exposure, although FDA approval, labeling, and safe-use requirements would control the viability of that strategy.

After expiration, the patent no longer creates a generic-entry risk. Current competition is governed by FDA approval requirements, manufacturing capability, product quality, supply, pharmacovigilance, and any unexpired patents separate from US 5,180,715.

What manufacturing and geographic barriers remain?

US 5,180,715 contains no manufacturing claims. It does not restrict production of sodium pentosan polysulfate, encapsulation, purification, or packaging after expiration.

Its geographic scope was limited to the United States. A US patent cannot block conduct occurring entirely outside the US, although US importation, US sales, or conduct directed toward US patients can create separate jurisdictional issues while a patent remains in force.

The relevant present-day barriers are therefore regulatory and operational rather than those created by this patent:

FDA approval of the generic product;
Demonstration of pharmaceutical equivalence and bioequivalence;
Control of active pharmaceutical ingredient quality;
Compliance with current good manufacturing practices;
Commercial-scale supply;
Stability and capsule manufacturing;
Postmarketing safety obligations.

These barriers do not restore exclusivity to the expired patent.

How does US 5,180,715 compare with a composition or formulation patent?

Issue	US 5,180,715	Composition patent	Formulation patent
Claims active ingredient itself	No	Usually yes	Usually no
Claims therapeutic use	Yes	Sometimes	Sometimes
Claims capsule ingredients	No express claim	Sometimes	Yes
Requires specific indication	Yes	Usually no	Sometimes
Requires route of administration	Yes	Usually no	Often yes
Generic design-around potential	Relatively high	Low before expiration	Moderate
Current enforceability	Expired	Depends on patent	Depends on patent

This distinction is central to freedom-to-operate analysis. A generic manufacturer can generally practice the expired use claims without infringement, but it must separately evaluate any other unexpired patents covering formulation, dosing, manufacturing, or labeling.

Key Takeaways

US 5,180,715 is a method-of-treatment patent for sodium pentosan polysulfate.
Claims 1-8 cover intravesical irrigation for bladder infections or interstitial cystitis.
Claims 9-11 cover oral treatment of interstitial cystitis.
The patent specifies saline and concentration or dose ranges only in dependent claims.
It does not claim the active ingredient, a capsule formulation, a manufacturing process, or a delivery device.
The patent issued January 19, 1993, and expired in 2010.
It no longer creates a live US patent barrier to generic pentosan polysulfate.
Elmiron was FDA approved under NDA 020193 for bladder pain or discomfort associated with interstitial cystitis.
Biosimilar risk is not applicable because sodium pentosan polysulfate is a small-molecule drug.
Any current freedom-to-operate analysis must focus on patents other than US 5,180,715, FDA requirements, and commercial manufacturing constraints.

FAQs

Does US Patent 5,180,715 cover Elmiron capsules directly?

No. The patent covers methods of using sodium pentosan polysulfate. It does not expressly claim the Elmiron capsule formulation as a composition.

Could a generic manufacturer still infringe US 5,180,715?

No, not based on post-expiration conduct. The patent expired in 2010, so it cannot support ordinary infringement liability for later manufacture, sale, or use.

Did US 5,180,715 cover treatment outside interstitial cystitis?

Yes. Claims 1-4 cover treatment of bladder infections by intravesical irrigation. Claims 5-11 address interstitial cystitis through irrigation or oral administration.

What dose does the patent associate with oral treatment?

Claim 10 covers at least about 100 mg per day. Claim 11 narrows the range to about 150-300 mg per day. Claim 9 itself does not specify a minimum daily dose.

Is a pentosan polysulfate biosimilar required for follow-on entry?

No. Sodium pentosan polysulfate is a small-molecule drug. Follow-on manufacturers use the generic-drug pathway, generally through an ANDA, rather than the biosimilar pathway.

References

United States Patent and Trademark Office. (1993). Treatment of interstitial cystitis with pentosan polysulfate (U.S. Patent No. 5,180,715).
U.S. Food and Drug Administration. (n.d.). Elmiron prescribing information, NDA 020193.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term information resources.
United States Patent and Trademark Office. (1994). Pentosan polysulfate compositions and methods of use (U.S. Patent No. 5,362,718).

Details for Patent: 5,180,715

Summary for Patent: 5,180,715